Rifampicin + Isoniazid + Pyrazinamide + Kanamycin + Moxifloxacin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Dec 29, 2008 → Dec 29, 2017
NCT ID
NCT00816426About Rifampicin + Isoniazid + Pyrazinamide + Kanamycin + Moxifloxacin
Rifampicin + Isoniazid + Pyrazinamide + Kanamycin + Moxifloxacin is a phase 1 stage product being developed by Novartis for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00816426. Target conditions include Tuberculosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00816426 | Phase 1 | Completed |
Competing Products
20 competing products in Tuberculosis